Why Have Clinical Trials of Antioxidants to Prevent Neurodegeneration Failed? - A Cellular Investigation of Novel Phenothiazine-Type Antioxidants Reveals Competing Objectives for Pharmaceutical Neuroprotection
Tóm tắt
Từ khóa
Tài liệu tham khảo
Halliwell B. Oxidative stress and neurodegeneration: where are we now? J Neurochem. 2006;97:1634–58.
Moosmann B, Behl C. Antioxidants as treatment for neurodegenerative disorders. Expert Opin Investig Drugs. 2002;11:1407–35.
Margaill I, Plotkine M, Lerouet D. Antioxidant strategies in the treatment of stroke. Free Radic Biol Med. 2005;39:429–43.
O’Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol. 2006;59:467–77.
Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007;357:562–71.
Green AR, Ashwood T. Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers. Curr Drug Targets CNS Neurol Disord. 2005;4:109–18.
The RANTTAS Investigators. A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). Stroke. 1996;27:1453–8.
Yamaguchi T, Sano K, Takakura K, Saito I, Shinohara Y, Asano T, et al. Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group. Stroke. 1998;29:12–7.
Toyoda K, Fujii K, Kamouchi M, Nakane H, Arihiro S, Okada Y, et al. Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion. J Neurol Sci. 2004;221:11–7.
Watanabe T, Tahara M, Todo S. The novel antioxidant edaravone: from bench to bedside. Cardiovasc Ther. 2008;26:101–14.
Hyslop PA, Zhang Z, Pearson DV, Phebus LA. Measurement of striatal H2O2 by microdialysis following global forebrain ischemia and reperfusion in the rat: correlation with the cytotoxic potential of H2O2 in vitro. Brain Res. 1995;671:181–6.
Seet RC, Lee CY, Chan BP, Sharma VK, Teoh HL, Venketasubramanian N, et al. Oxidative damage in ischemic stroke revealed using multiple biomarkers. Stroke. 2011;42:2326–9.
Granold M, Moosmann B, Staib-Lasarzik I, Arendt T, Del Rey A, Engelhard K, et al. High membrane protein oxidation in the human cerebral cortex. Redox Biol. 2015;4:200–7.
Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke. 2009;40:2244–50.
Zhang Q, Pi J, Woods CG, Andersen ME. A systems biology perspective on Nrf2-mediated antioxidant response. Toxicol Appl Pharmacol. 2010;244:84–97.
Müller M, Banning A, Brigelius-Flohé R, Kipp A. Nrf2 target genes are induced under marginal selenium-deficiency. Genes Nutr. 2010;5:297–307.
Nakamura Y, Miyoshi N. Electrophiles in foods: the current status of isothiocyanates and their chemical biology. Biosci Biotechnol Biochem. 2010;74:242–55.
Macleod MR, van der Worp HB, Sena ES, Howells DW, Dirnagl U, Donnan GA. Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality. Stroke. 2008;39:2824–9.
Savitz SI. A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp Neurol. 2007;205:20–5.
Kuroda S, Tsuchidate R, Smith ML, Maples KR, Siesjö BK. Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab. 1999;19:778–87.
Barclay LR, Vinqvist MR. Do spin traps also act as classical chain-breaking antioxidants? A quantitative kinetic study of phenyl tert-butylnitrone (PBN) in solution and in liposomes. Free Radic Biol Med. 2000;28:1079–90.
Floyd RA, Kopke RD, Choi CH, Foster SB, Doblas S, Towner RA. Nitrones as therapeutics. Free Radic Biol Med. 2008;45:1361–74.
Behl C, Moosmann B. Oxidative nerve cell death in Alzheimer’s disease and stroke: antioxidants as neuroprotective compounds. Biol Chem. 2002;383:521–36.
Ohlow MJ, Mocko JB, Behl C, Hajieva P, Moosmann B. Comparative evaluation of biochemical antioxidants as neuroprotective agents. Free Radic Biol Med. 2010;49:S192.
Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med. 1993;328:176–83.
Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002;59:1541–50.
Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352:2379–88.
Thal LJ, Grundman M, Berg J, Ernstrom K, Margolin R, Pfeiffer E, et al. Idebenone treatment fails to slow cognitive decline in Alzheimer’s disease. Neurology. 2003;61:1498–502.
Matthews RT, Yang L, Browne S, Baik M, Beal MF. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci U S A. 1998;95:8892–7.
Vatassery GT, Fahn S, Kuskowski MA. Alpha tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. Neurology. 1998;50:1900–2.
Gohil K, Oommen S, Quach HT, Vasu VT, Aung HH, Schock B, et al. Mice lacking alpha-tocopherol transfer protein gene have severe alpha-tocopherol deficiency in multiple regions of the central nervous system. Brain Res. 2008;1201:167–76.
Hajieva P, Mocko JB, Moosmann B, Behl C. Novel imine antioxidants at low nanomolar concentrations protect dopaminergic cells from oxidative neurotoxicity. J Neurochem. 2009;110:118–32.
Crivello JV. Benzophenothiazine and benzophenoxazine photosensitizers for triarylsulfonium salt cationic photoinitiators. J Polym Sci A Polym Chem. 2008;46:3820–9.
Moosmann B, Skutella T, Beyer K, Behl C. Protective activity of aromatic amines and imines against oxidative nerve cell death. Biol Chem. 2001;382:1601–12.
Re R, Pellegrini N, Proteggente A, Pannala A, Yang M, Rice-Evans C. Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Radic Biol Med. 1999;26:1231–7.
Triguero D, Buciak J, Pardridge WM. Capillary depletion method for quantification of blood–brain barrier transport of circulating peptides and plasma proteins. J Neurochem. 1990;54:1882–8.
Seelig A, Gottschlich R, Devant RM. A method to determine the ability of drugs to diffuse through the blood–brain barrier. Proc Natl Acad Sci U S A. 1994;91:68–72.
Lien EJ, Ren S, Bui HH, Wang R. Quantitative structure-activity relationship analysis of phenolic antioxidants. Free Radic Biol Med. 1999;26:285–94.
Tan S, Sagara Y, Liu Y, Maher P, Schubert D. The regulation of reactive oxygen species production during programmed cell death. J Cell Biol. 1998;141:1423–32.
Schubert D, Piasecki D. Oxidative glutamate toxicity can be a component of the excitotoxicity cascade. J Neurosci. 2001;21:7455–362.
Ohlow MJ, Moosmann B. Phenothiazine: the seven lives of pharmacology’s first lead structure. Drug Discov Today. 2011;16:119–31.
Musiek ES, Yin H, Milne GL, Morrow JD. Recent advances in the biochemistry and clinical relevance of the isoprostane pathway. Lipids. 2005;40:987–94.
Chevion M, Berenshtein E, Stadtman ER. Human studies related to protein oxidation: protein carbonyl content as a marker of damage. Free Radic Res. 2000;33(Suppl):S99–108.
Comellas AP, Dada LA, Lecuona E, Pesce LM, Chandel NS, Quesada N, et al. Hypoxia-mediated degradation of Na,K-ATPase via mitochondrial reactive oxygen species and the ubiquitin-conjugating system. Circ Res. 2006;98:1314–22.
Sotiriou S, Gispert S, Cheng J, Wang Y, Chen A, Hoogstraten-Miller S, et al. Ascorbic-acid transporter Slc23a1 is essential for vitamin C transport into the brain and for perinatal survival. Nat Med. 2002;8:514–7.
Huang J, Agus DB, Winfree CJ, Kiss S, Mack WJ, McTaggart RA, et al. Dehydroascorbic acid, a blood–brain barrier transportable form of vitamin C, mediates potent cerebroprotection in experimental stroke. Proc Natl Acad Sci U S A. 2001;98:11720–4.
Ohlow MJ, Granold M, Schreckenberger M, Moosmann B. Is the chromanol head group of vitamin E nature’s final truth on chain-breaking antioxidants? FEBS Lett. 2012;586:711–6.
Lanigan RS, Yamarik TA. Final report on the safety assessment of BHT. Int J Toxicol. 2002;21 Suppl 2:S19–94.
Mocko JB, Kern A, Moosmann B, Behl C, Hajieva P. Phenothiazines interfere with dopaminergic neurodegeneration in Caenorhabditis elegans models of Parkinson’s disease. Neurobiol Dis. 2010;40:120–9.
Freyschuss A, Al-Schurbaji A, Björkhem I, Babiker A, Diczfalusy U, Berglund L, et al. On the anti-atherogenic effect of the antioxidant BHT in cholesterol-fed rabbits: inverse relation between serum triglycerides and atheromatous lesions. Biochim Biophys Acta. 2001;1534:129–38.
Tymianski M. Can molecular and cellular neuroprotection be translated into therapies for patients? Yes, but not the way we tried it before. Stroke. 2010;41 Suppl 10:S87–90.
Hill MD, Martin RH, Mikulis D, Wong JH, Silver FL, Terbrugge KG, et al. Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2012;11:942–50.
Murphy TH, Miyamoto M, Sastre A, Schnaar RL, Coyle JT. Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. Neuron. 1989;2:1547–58.
Li Y, Maher P, Schubert D. A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion. Neuron. 1997;19:453–63.
Long LH, Hoi A, Halliwell B. Instability of, and generation of hydrogen peroxide by, phenolic compounds in cell culture media. Arch Biochem Biophys. 2010;501:162–9.
Wijtmans M, Pratt DA, Brinkhorst J, Serwa R, Valgimigli L, Pedulli GF, et al. Synthesis and reactivity of some 6-substituted-2,4-dimethyl-3-pyridinols, a novel class of chain-breaking antioxidants. J Org Chem. 2004;69:9215–23.
Omata Y, Saito Y, Yoshida Y, Jeong BS, Serwa R, Nam TG, et al. Action of 6-amino-3-pyridinols as novel antioxidants against free radicals and oxidative stress in solution, plasma, and cultured cells. Free Radic Biol Med. 2010;48:1358–65.
Lasarzik I, Thal SC, Jahn-Eimermacher A, Engelhard K, Moosmann B. NH-Phenothiazine dose-dependently improves neuronal outcome after cerebral ischemia in rats. Proceedings of the 2010 Annual Meeting of the American Society of Anesthesiologists (ASA), San Diego, CA, USA. Abstract A1046.
Yu MJ, McCowan JR, Smalstig EB, Bennett DR, Roush ME, Clemens JA. A phenothiazine derivative reduces rat brain damage after global or focal ischemia. Stroke. 1992;23:1287–91.
Tapias V, Mastroberardino PG, Hu X, Nelson J, Sew T, Greenamyre JT. Unsubstituted Phenothiazine is protective in the rotenone model of Parkinson’s disease. Neuroscience Meeting, New Orleans, LA, USA: Society for Neuroscience, 2012. Program No. 856.11.
Songarj P, Luh C, Staib-Lasarzik I, Engelhard K, Moosmann B, Thal SC. The antioxidative, non-psychoactive tricyclic phenothiazine reduces brain damage after experimental traumatic brain injury in mice. Neurosci Lett. 2015;584:253–8.
Murphy CM, Rawer H, Smith NL. Mode of action of phenothiazine-type antioxidants. Ind Eng Chem. 1950;42:2479–89.
Burton GW, Doba T, Gabe E, Hughes L, Lee FL, Prasad L, et al. Autoxidation of biological molecules. 4. Maximizing the antioxidant activity of phenols. J Am Chem Soc. 1985;107:7053–65.
Shang YJ, Jin XL, Shang XL, Tang JJ, Liu GY, Dai F, et al. Antioxidant capacity of curcumin-directed analogues: Structure-activity relationship and influence of microenvironment. Food Chem. 2010;119:1435–42.
Moosmann B, Behl C. The antioxidant neuroprotective effects of estrogens and phenolic compounds are independent from their estrogenic properties. Proc Natl Acad Sci U S A. 1999;96:8867–72.
Shahidi F, Zhong Y. Revisiting the polar paradox theory: a critical overview. J Agric Food Chem. 2011;59:3499–504.
Ritchie TJ, Macdonald SJ, Young RJ, Pickett SD. The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types. Drug Discov Today. 2011;16:164–71.
Colmenarejo G, Alvarez-Pedraglio A, Lavandera JL. Cheminformatic models to predict binding affinities to human serum albumin. J Med Chem. 2001;44:4370–8.
Wasan KM, Brocks DR, Lee SD, Sachs-Barrable K, Thornton SJ. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Nat Rev Drug Discov. 2008;7:84–99.
Gilgun-Sherki Y, Melamed E, Offen D. Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology. 2001;40:959–75.
Gao H, Pang Z, Jiang X. Targeted delivery of nano-therapeutics for major disorders of the central nervous system. Pharm Res. 2013;30:2485–98.
Hajieva P, Bayatti N, Granold M, Behl C, Moosmann B. Membrane protein oxidation determines neuronal degeneration. J Neurochem. 2015;133:352–67.